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Routine administration of erythropoietin (EPO)-stimulating
agents (ESAs) for the control of anemia has improved the
quality of life of subjects with chronic kidney disease (CKD).
However, a wide variation in individual response to ESA is
often observed. The reasons for EPO resistance include
demographic variables such as age and gender distribution,
morbidity pattern, and modality of dialysis. Despite
suggestions by observational data, there is no biological
characteristic that puts children at a disadvantage for
adequate response to ESA. On the contrary, children
possess a superior capacity for red cell production, including
extramedullary erythropoiesis. The reasons for larger
requirement of ESA in children (than in adults) are greater
inflammatory burden, disproportionate blood loss, and
greater EPO dosing by pediatric physicians. To minimize the
harmful (including fatal) consequences of EPO resistance,
surveillance programs must replenish nutrient (for example,
iron and folate) stores, minimize oxidative hemolysis, control
hyperparathyroidism, avoid catheter infection, and optimize
uremic clearance. This clinical approach is justified by the
inadequacy of laboratory diagnosis of pertinent etiological
factors. Indeed, the best proof for functional nutrient
deficiency is often a therapeutic trial. Finally, there are
upcoming therapeutic agents that exploit the capacity for
an endogenous EPO synthesis in CKD subjects, and may
therefore minimize the off-target effect of excess dosages.
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In the absence of standard diagnosis criteria, studies on resis-
tance to erythropoietin (EPO)-stimulating agents (ESAs) have
depended on ad hoc definitions. Consequently, there is inability
to compare data obtained from multiple sources. Data from the
United States Renal Data System showed that there is a wide
variation in the dosing pattern of ESAs in the renal popu-
lation.1–4 Thus, the mean EPO doses given to the top 99th
percentile are 30 times larger than the amount received by
the lower 1%. Target hemoglobin (Hb) mass (11–12 g/dl) is
only achieved in 90–95% of patients after treatment with
1000–30, 000 IU/week of short-acting ESAs.1–4 In general, ESA
resistance is presumed in adult subjects if Hb mass is o11 g/dl
(over a 4–6-month period) despite a weekly dose of EPO in excess
of 500 IU/kg or 30, 000 IU/week (X1.5mg/kg for darbepoietin).
However, there are insufficient data in the pediatric
population that will allow generation of a similar definition.
Nevertheless, according to the 2004 NAPRTCS (North
American Pediatric Renal Transplant Cooperative Study)
data, the average dosing requirement for EPO in pediatric
subjects is 350 IU/kg.2 The disproportionate larger doses of
EPO in children are concerning and may in part reflect the
extrapolation of adult-dosing regimen by pediatric physicians.5
A more equitable dosing may be achieved using absolute Hb
deficit and/or body surface area (greater correlation with blood
volume) as criteria for prescription. Furthermore, there is a
greater prevalence of amenable etiological factors of ESA
resistance in pediatric subjects than in adults.5 Therefore, it
may be reasonable to adopt a lower threshold of EPO dosing
for pediatric diagnosis. Thus, evaluation of ESA resistance
should be commenced if Hb mass iso11 g/dl (over a 3-month
period) in spite of a weekly dose of EPO of 4400 IU/kg or
420, 000 IU/week (X1.0mg/kg for darbepoietin).
Although standardized definition has its usefulness, care
must be taken not to fall prey to its unintended con-
sequences. We must recognize the role of poorly amenable
risk factors of ESA resistance: including female menstrual
status, androgen deficit in elderly males, dialysis modality,
and age-related comorbidities. Hence, the rationale for an
individual evaluation should be based on clinical judgment
and demographic peculiarities.
Harmful effects of ESA resistance
A recent meta-analysis of studies evaluating higher Hb target
with the use of ESA in chronic kidney disease (CKD) suggests
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there is a greater risk for stroke, cardiovascular events, and
mortality rate.6–9 However, it is not clear whether the adverse
outcomes are related to EPO dosing, higher Hb mass, or
some (hidden) variables. Nevertheless, there is an undoubted
need for a cautious dosing of ESA, whereas adequate
knowledge of its independent effect will require randomized
clinical trials.
Similarly in a geriatric cohort study, there is a correlation
between higher concentration of endogenous EPO and fatal
outcome.10 Although this finding may reflect a physiological
response to an undiagnosed hypoxemia, impaired bone
marrow response (senescence) is not unlikely.10 Hence, the
resultant excessive EPO synthesis may promote off-target
biological consequences. Furthermore, a recent study has
suggested that a segment of hemodialysis (HD) population
may maintain natural Hb mass in excess of 12 g/dl without
a greater mortality rate.11 Given the complexity of EPO
resistance, a careful analysis of its etiology and appropriate
intervention are often warranted.
ETIOLOGY OF ESA RESISTANCE
The pattern of risk factors in a dialysis program is dependent
on sociodemographic variables, mode of clinical practice, and
quality of renal care.12 Methodology including the choice of
diagnostic parameters often influences the outcome of the
studies.
Age and gender
Despite suggestions by observational data, there is no innate
biological characteristic that puts children at a disadvantage
for an adequate response to ESA. On the contrary, children
are known to have a superior capacity for hematopoiesis,
including the use of an extramedullary organ (such as the
spleen) when necessary.13 In a recent comparative study of
pediatric and adult dialysis cohorts, a ten-times larger dose of
ESA was required in the younger cohort. The reason for the
disparity includes greater inflammatory stress and dispropor-
tionate blood loss.14 Furthermore, the findings of a greater
need of EPO in adult females may be due to androgenic
stimulation of erythropoiesis in males.15 Similarly, women
with preserved capacity for menstrual cycles, despite the
hypogonadotrophic effect of CKD, often require greater
amounts of EPO.16
Uremia and ESA resistance
Although the mechanism is uncertain, there is reduced renal
capacity to synthesize EPO in chronic uremia, whereas there
is blunted bone marrow response to its biological action
(Table 1). Nevertheless, as a result of persistent stimulation
from pervasive anemia, there is a five-fold higher than
normal EPO concentration for the level of Hb deficit.17
Finally, clinical evidence of uremic inhibition is demon-
strated by the correlation of urea nitrogen clearance with
improved cytokine profiles (interleukin (IL)-6, C-reactive
proteins) and lower requirement for ESA.18
Outside of the poor bone marrow response to ESA, there
is an accelerated turnover rate of red cells from persistent
oxidative stress, increased osmotic fragility, and progressive
depletion of adenosine triphosphate (ATP). Uremia alters
erythrocyte morphology by inducing outward expression of
the phosphatidyl-serine content of its inner membrane,
which is removed by circulating macrophages.19,20 In addi-
tion, there is impaired cellular generation of ATP by uremic
inhibition of pentose phosphate shunt and tricarboxylic acid
cycle.21,22 These cells, which are depleted of ATP, manifest
poor capacity for cytosolic calcium efflux and thereby inhibit
mitochondrial oxidative phosphorylation, thus, setting up a
vicious cycle.23,24
Oxidative stress, anemia, and ESA response
Oxidative stress promotes ESA resistance by causing lipid
peroxidation of red cell membranes.25 It depletes the capacity
for ATP generation by interfering with mitochondrial func-
tion (Table 1). Uremia in turn enhances cellular oxidation by
increasing the activity of superoxide dismutase.26 Further-
more, renal retention of asymmetric dimethyl arginine, and
low cellular content of L-arginine analog, inhibits synthesis
of its nitric oxide metabolite.27 The magnitude of (uremic)
Table 1 | The risk factors, pathogeneses, and therapeutic modulation of erythropoietin resistance in pediatric and adult
subjects with chronic kidney disease
Risk factors Mechanism of ESA resistance Therapeutic intervention
Uremic toxinsa,b kEPO synthesis/kerythroid response Longer effective dialysis
Oxidative stressa,b Downregulation of HIF Vit E and vit C
Inflammationa,b,c Cytokines: IL-1, IL-6, TNF-a Avoid sepsis and malnutrition
Iron deficiencya,c Hemoglobin synthesis Replenish iron/k blood loss
Hyperparathyroidisma,c Vitamin D synergism (erythropoiesis) Low P diet/ 1,25 OH vit D
Aluminum toxicitya,c Aluminum bone disease Avoid aluminum intake
Hemolysisa,c Uremia/HbSS/G6PDD/AIHA Uremic clearance/vit E and C
Drugs: angiotensin-modulating agentsa,b kErythroid ANG II receptors/mendogenous EPO inhibitor, AcSDKP kDose of ACEi/ARB
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; AcSDKP, N-acetyl-seryl-aspartyl-lysyl-proline; AIHA, autoimmune hemolytic anemia; ANG, angiotensin;
ARB, angiotensin receptor blocker; EPO, erythropoietin; ESA, EPO-stimulating agent; G6PDD, glucose 6-phosphatase deficiency; HbSS, hemoglobinopathies; HD, hemodialysis;
HIF, hypoxic-inducible factor; IL, interleukin; TNF-a, tumor necrosis factor-a; vit, vitamin.
aAdult data; applicable to both populations.
bExperimental data; applicable to both populations.
cPediatric and adult data.
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oxidative burden is made worse by the reduction in erythro-
cyte glutathione, an anti-oxidant tripeptide, by extra-
corporeal exposure to dialyzer membranes.28
The pro-oxidative renal tissue downregulates the genera-
tion of hypoxic-inducible factor-1 alpha (HIF-1a) protein,
thereby reducing EPO synthesis and red cell production.29
This contributes to pervasive anemia, which in turn, increases
the fragility of erythrocyte by membrane (lipid) peroxida-
tion.25 Therefore, to break the vicious cycle, correction of
anemia seems like a cost-effective strategy.
EPO is a pleiotropic hormone that is crucial for anemia
control and suppression of oxidative stress by upregulation
of heme oxygenase-1.30 It protects the animal model of
ischemia–reperfusion by activation of the cell survival signal
pathways.31 However, adjunct therapy with iron elaborates
free oxygen radicals and may potentially reverse the anti-
oxidative benefit of ESA.32,33
Inflammation and ESA resistance
Careful data analysis often suggests that persistent inflamma-
tion is a confounding variable in fatality associated with
CKD. Contributory factors are bio-incompatible dialyzers,
dialysate (water) contamination, long duration of HD
catheters, poor dialysis, and previous allograft rejection
(Table 1).
Cytokines and ESA. Uremic toxins are implicated in the
propagation of proinflammatory cytokines: IL-1, IL-6,
interferon-g, and tumor necrosis factor.34,35 These cytokines
downregulate the expression of EPO receptors on erythroid
progenitors and disrupt iron recycling by blocking its release
from reticuloendothelial cells (Figure 1).36
In normal circumstances, macrophages ingest the senes-
cent erythrocyte and release its iron contents into the
lysosomes. Ferrous ions are then transported across the cell
membrane by ferroportin carrier protein. The latter is inhib-
ited by hepcidin, an acute-phase reactant that is synthesized by
the liver after stimulation by IL-6.37 Iron is transported in the
plasma by the transferrin carrier protein, which enhances its
cellular uptake by binding to its surface receptors.38 Cytokines
may also upregulate iron cellular uptake by activating divalent
metal transporter and/or transferrin.38
Mechanism of EPO receptor activation. EPO binds to
erythroid cell by spontaneous dimerization of its surface
receptors (Figure 2). The persistent activation allows for
interaction with receptor even at a low EPO concentration.39
Resistance to ESA may result from defective dimerization of
EPO receptors. Similarly, activation of the EPO receptor is
prevented by (antagonistic) a mimetic peptide such as
cytokine-inducible SH2-containing protein.40
After binding to its receptor, EPO activates JAK2 tyrosine
kinase, which in turns promotes intracellular phosphory-
lation leading to initiation of a signal transduction.40 In
addition, by regulating the activation of EPO receptors,
tyrosine phosphatase (SHP-1) desphophorylates JAK2.41
Hence, there is serum elevation of SHP-1 in HD subjects
with ESA resistance.41
In response to the activation of intracellular domain of
the EPO receptor, both signal transducer and activator of
transcription-5 (STAT-5) and nuclear factor kB are phos-
phorylated. These pathways then upregulate mitochondrial
expression of (anti-apoptotic) Bcl-xl and Bcl-2 proteins,
thereby promoting erythroid cell proliferation.42,43 In addi-
tion, STAT-5 participates in negative regulatory feedback and
induces suppressor of cytokine signaling (or cytokine-induc-
ible SH2-containing protein), which in turn downregulates
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Figure 1 | Schematic illustration of erythropoietin receptor
activation and intracellular signal transduction. CKD, chronic
kidney disease; DMT1, divalent methyl transporter-1; RBC, red
blood cell; TfR, transferrin receptor.
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Figure 2 |Process of physiological iron recycling involving
macrophages and enterocytes. EPO, erythropoietin; HCP,
hematopoietic cell phosphatase; NFkB, nuclear factor kB; JAK2,
Janus kinase 2; P, phosphorylation; TP, tyrosine phosphatase;
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signal transduction by preventing JAK2 phosphorylation of
the EPO receptor.44 Similarly, hematopoietic cell phosphatase
inactivates JAK2. Suppressor of cytokine signaling may also
inhibit EPO effect by a direct inactivation of STAT-5.
Proinflammatory cytokines promote EPO resistance by
activation of suppressor of cytokine signaling and subsequent
inhibition of nuclear factor kB.44–46
Failed allograft and ESA. It is estimated that 4.5% of
B10, 000 subjects on maintenance dialysis in the United
States, between the years 1996 and 2001, have had at least
one failed allograft. In spite of the larger EPO requirement in
this sub-group, there is 50% higher incidence of anemia,
greater decline in kidney function, and a lower survival rate
compared with controls.47 If the etiological role of failed
allograft is suspected, therapeutic care must be individua-
lized. The risk of transplant nephrectomy must be carefully
weighed against the clinical benefits. In the events of
symptoms of transplant rejection, persistent elevation of
inflammatory indices, and intractable anemia despite large
doses of ESA, nephrectomy is a reasonable approach.48
Dialysis catheters. Additional sources of oxidative inflam-
mation are the use of perm-cath and synthetic grafts as
vascular access in HD subjects.49 Even in the absence of
infection, compared with arteriovenous fistula, HD catheters
and synthetic arteriovenous grafts promote systemic in-
flammation.50,51 Compared with subjects using native
arteriovenous fistulae, larger doses of effective ESA and
greater need for blood transfusion are observed in those
dialyzed with using artificial vascular access.51 Furthermore,
routine use of anti-platelet prophylaxis may aggravate iron
deficiency among patients dialyzed with AV grafts.
Finally, to minimize the adverse impact of inflammation,
optimal control of uremic toxicity is necessary. In this regard,
nocturnal HD has been shown to enhance clearance of
middle molecules, suppress inflammatory (IL-6) cytokines,
and thereby reduces ESA requirement.52
Iron deficiency and ESA resistance
Iron deficiency, principally due to poor nutrition, is not only
common in CKD but is also most probably a universal
occurrence in dialysis subjects (Table 1; Figure 3). There is an
estimated annual loss of 2 g of elemental Fe among adult
subjects on maintenance HD.53 Aggravating iron deficiency
in end-stage kidney disease is the depletion of tissue store by
the supra-physiological proliferation of erythroid cells that
results from ESA therapy.54 As a result of frequent blood
sampling, smaller body mass, higher rate of catheter use, and
greater incidence of infection, pediatric subjects are more
susceptible to iron deficiency.12 Additional source of iron loss
is uremic gastritis; its incidence may be potentiated by a
concomitant infection with Helicobacter pylori.55
There is good evidence that suggest that adjunct use of
intravenous iron with ESA is a cost-effective strategy for
anemia control in chronic HD.56 For this reason, routine
evaluation of iron repletion is often necessary. Serum iron
and transferrin saturation provide a modest but effective
means of assessing iron bioavailability, whereas adequacy of
tissue stores can be estimated with total iron-binding
capacity and ferritin. Low serum ferritin is an early indicator
of iron deficiency, but a high serum value may be confounded
by inflammatory status. Therefore, a minimum of two
indices of serum iron (o100mg/dl), transferrin saturation
(o20%), and serum ferritin (o100 ng/dl) is required to
make a diagnosis.57–59 Although oral iron is used as prophy-
laxis, because of superior efficacy, parenteral route is
frequently required for adequate repletion. To avoid systemic
overload during inflammation process, parenteral iron therapy
is withheld if serum ferritin level exceeds 500–800mg/dl,
Hb < 11 g/dl + ESA > 500 IU/kg × 12 wk ± TSAT > 20% and ferritin > 100 mg/dl
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Figure 3 | Schema for clinical evaluation of resistance to erythropoietin stimulating agent in chronic kidney disease. AIDS, acquired
immunodeficiency syndrome; AIHA, autoimmune hemolytic anemia; CMV, cytomegalovirus; CRP, C-reactive protein; ESA, erythropoietin-
stimulating agent; G6PD, glucose 6-phosphate dehydrogenase deficiency; Hb, hemoglobin; HD, hemodialysis; HPTH, hyperparathyroidism;
HUS, hemolytic uremia syndrome; ISA, immunosuppressive agents; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; PRCA, pure
red cell aplasia; SLE, systemic lupus erythematosis; TSAT, transferrin saturation.
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whereas vitamin C could be used to mobilize iron from
reticuloendothelial stores.57–59
Secondary hyperparathyroidism
Suggesting an etiological role of hyperparathyroidism, there
is a higher prevalence of anemia and greater EPO require-
ment among HD subjects who are in the upper 50th
percentile of intact parathyroid hormone.60,61 As a proof of
causal relationship, surgical parathyroidectomy led to an
improved control of anemia and a lower need for ESA.62
Nevertheless, there is no evidence for a direct inhibition of
erythropoiesis by excessive PTH. Neither is there a proof of
associated bone marrow fibrosis in experimental animals.63
On the contrary, there is a positive correlation between serum
PTH and systemic mobilization of progenitor cells in primary
hyperparathyroidism.64
Resistant anemia is more likely a result of complex
interaction of uremic toxins, PTH, and inflammatory
cytokines (Table 1). An evidence for this assertion is the
downregulation of bone cell expression of PTH, transforming
growth factor-b, and insulin-like growth factor-1 receptors in
uremia, whereas there is altered response to IL-1, IL-6, and
tumor necrosis factor-a cytokines.65 In addition, metabolic
acidosis and hyperphosphatemia may underlie the resistance
to ESA in uremic bone disease. Both conditions down-
regulate EPO receptors by causing a rightward shift of the
oxygen–Hb dissociation curve. This theory was supported by
a regression analysis that showed a correlation between ESA
resistance and hyperphosphatemia, despite an adequate
control of PTH effect.66
Consequently, effective strategy for the control of
ESA resistance in metabolic bone disease must encompass
dialysis restoration of non-uremic homeostasis. In addition,
therapeutic modulation of uremic bone morphology may be
possible in the near future. Thus, treatment of uremic animal
with bone morphogenetic protein-7 not only maintained
the osteoblastic phenotype but also prevented bone marrow
fibrosis.67
1,25-vitamin D deficiency
Aggravating the capacity to synthesize the active form of
vitamin D in CKD is the inadequate exogenous supply of
25-OH vitamin D (Table 1; Figure 3). Low serum 25-(OH)
vitamin D (o65 nmol/l) occurs in 80% of subjects with
glomerular filtration rate of 20–90ml/min per 1.73m2.
Reasons for deficiency include poor sunlight exposure,
deficient skin synthesis, low dietary intake, and nephrotic
urinary losses.68–70 In addition to the role of vitamin D in
bone mineral metabolism, pleiotropy is suggested by a wide
receptor distribution and its synergistic effect on ESA control
of anemia.71 In a similar manner, calcitriol treatment in
subjects with uremic bone disease increases the proliferation
of erythroid precursors.72 Corroborating the evidence for
synergism is a lower EPO requirement among subjects with
BB polymorphism of vitamin D receptor genotype compared
with those with the heterozygous Bb/bb gene.73,74
Heavy metal
Subjects with stage 4–6 CKD are at risk for toxicity from
heavy metal because the renal route is the principal mode of
elimination (Table 1; Figure 3). Bone marrow function is
often impaired in individuals with heavy metal poisoning.75
Aluminum (Al) toxicity is a rare event in modern practice
because of discontinuation of its use as a phosphate binder,
and a lower Al content in dialysis water. However, inadver-
tent intake of Al-containing compounds may occur in
(developing) countries with poor control of pharmaceutical
standards.75 Heavy metal exposure (cadmium, lead, and
mercury) may result from industrial pollution. Similarly, the
use of alternative herbal supplements is not uncommon even
among the educated elites. Some folk remedies of Indian and
Middle Eastern origins are enriched with heavy metals (rasa
shastra) based on a presumed therapeutic efficacy.76
Furthermore, close to 16% of children inhabitants of cities
with a population greater than one million, who reside in
homes built before 1946, have elevated lead levels.77 Although
there are no available data, lead toxicity is more likely to
occur in patients with CKD. This is because both iron and
calcium deficiencies, commonly seen in CKD, increase the
gastrointestinal absorption of heavy metals.78 In addition,
uremia may increase mobilization of lead from bone tissue
stores. In general, lead toxicity causes anemia by precluding
incorporation of iron into a protoporphyrin ring for heme
synthesis.78
Hemoglobinopathy and hemolytic anemia
Anemia in CKD subjects, perpetuated by comorbid hemato-
logical disorders (B-thal, HbS, HbA2, HbH), is frequently
associated with elevated endogenous EPO (Figure 3).79 The
most common hemoglobinopathy is sickle cell disease. It
occurs more frequently in individuals of African, Mediterra-
nean, South American, Asian, and Middle Eastern descent.79–81
The mechanism of EPO resistance includes bone marrow
infarction, red cell hemolysis, hypersplenism, and ineffective
erythropoiesis.79,80 As newborn screening is mandated in most
developed economies, most patients with hemoglobinopathies
are identified before the onset of CKD.82 In addition, the recent
trend of improving quality of care (with a longer survival) and
insidious onset of renal consequence make end-stage kidney
disease an unlikely event in pediatric subjects, while prevalence
in adult program is expected to increase.82,83
In view of its low prevalence, data on the impact of
hemoglobinopathy on EPO-resistant anemia are rare. In a
recent Italian study of HD subjects with b-thalassemia minor,
correlation was found between higher doses of ESA and
plasma content of Hb A2.84 Therefore, it is desirable to
consider the role of Hb disease in ESA resistance in endemic
(geographical) area that lacks newborn screening programs.
Even in the developed world, there should be awareness of its
confounding effect among immigrant subjects and/or those
with enhanced ethnic susceptibility.
Subjects with chronic uremia and hemolytic diseases are
more susceptible to the morbid impact of oxidative stress,
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nutrient deficiency, and dialysis blood loss (Table 1).
Common chronic hemolytic conditions are sickle cell disease,
thalassemia, hereditary spherocytosis, glucose 6-phosphate
dehydrogenase deficiency, and auto-immune diseases.85
Similar to hemoglobinopathy, there is ethnic susceptibility
to glucose 6-phosphate dehydrogenase deficiency. It occurs in
13% of Black males and in 2% of Black females.85
In subjects with CKD that is preceded by systemic lupus
erythematosis and hemolytic uremia syndrome, relapses
must be evaluated in the event of intractable anemia
(Figure 3). Autoimmune hemolytic anemia occurs in
5–10% of patients with systemic lupus erythematosis; it is
frequently associated with renal or neurological involve-
ment.86–88 As reticulocytosis is common in patients on ESA
therapy, early diagnosis of hemolytic events may be missed. It
should be suspected when there is a progressive increase in
EPO requirement while there is rapidly decreasing Hb
concentration. An additional clue to autoimmune process
in systemic lupus erythematosis is the concurrent depression
of megakaryocytic cell line. Serum titer of anti-double-
stranded DNA is often elevated.88
Unlike the more common diarrhea-associated hemolytic
uremia syndrome, the atypical form is often more severe,
relentless, and frequent.89 Its etiology may include the
absence of regulatory inhibition of complement C3 activity,
which results from hereditary factor H deficiency. Similarly,
deficiency of von Willebrand factor cleaving-protease
activity predisposes to recurrent micro-angiopathic episodes.
Both events may be temporarily controlled by infusion
of fresh frozen plasma. Furthermore, transplant hemo-
lytic uremia syndrome may occur (de novo) particularly
among patients exposed to calcineurin inhibitors, those
who had bone marrow transplant and/or acute viral
infection.89
Angiotensin-modulating agents
The influence of angiotensin-converting enzyme inhibitor/
angiotensin receptor blockers on ESA resistance is contro-
versial. A range of studies, mostly observational, have either
suggested an etiological role or dismissed that there is a
causal association (Table 1). A prototype study showed
there is a higher EPO requirement in dialysis patients who
were treated for hypertension with either angiotensin-
converting enzyme inhibitors or angiotensin receptor block-
ers compared with those placed on calcium channel
blockers.90 A genetic mechanism for angiotensin modulation
is suggested by a favorable response to ESA in dialysis
subjects with insertion/deletion ACE polymorphism.91
Furthermore, angiotensin-converting enzyme inhibitor sup-
presses the enzymatic degradation of N-acetyl-seryl-aspartyl-
lysyl-proline (AcSDKP), a naturally occurring inhibitor of
erythropoiesis.92 Similarly, stimulation of erythroid cellular
proliferation by angiotensin binding of its type II surface
receptor is inhibited by angiotensin receptor blockers.93 This
forms the basis for the therapeutic use of angiotensin
receptor blockers in post-transplant erythrocytosis.
Route of administration
The subcutaneous route is considered a more effective means
of ESA delivery; it requires lower EPO dose than does the
intravenous route for the same biological effect.94 However, a
follow-up study showed no disparity in EPO requirement for
either subcutaneous or intravenous route if there is adequate
Fe repletion.95 The convenient use of intravenous therapy
makes it a preferred modality in HD programs, whereas
self-administered subcutaneous route is used in peritoneal
dialysis patients and non-dialysis CKD.
Non-iron micronutrients
The role of non-iron micronutrient deficiency in ESA
resistance is often underestimated (Figure 3).96 The extra-
ordinary ESA stimulation of bone marrow, high catabolism,
and losses with frequent dialysis are predisposing factors for
nutrient deficiency. The poor bioavailability of hemato-
poietic nutrients (folate, vitamins B12 and C) could limit the
efficiency for erythropoiesis. Micronutrient deficiency is a
potential contributory factor for greater mortality in subjects
that failed to attain Hb target despite large doses of EPO.7–9
Thus, in a longitudinal dialysis cohort, serum deficiency of
water-soluble vitamins (B1, B6, C, and folates) had resulted
from a substantial loss in 50% of patients. Lower amounts of
lipophilic vitamins (A and E) were measured in the
dialysates.97
Folate deficiency
Although folate deficiency is a rare finding in studies that
depend on serum sample for diagnosis, a greater EPO
requirement was observed in a pediatric dialysis cohort that
had hematological response to a therapeutic trial.96 Labora-
tory assay of serum folate is prone to error because of its poor
prediction of tissue stores.98–100 Etiologies of folate deficiency
in end-stage kidney disease may include poor gastrointestinal
absorption, poor diet, water-soluble nutrient loss, and high
catabolic rate.101–103 Folic acid is an essential ingredient for
nucleotide synthesis, DNA repair, and re-methylation of
homocysteine. Owing to its requirement for excessive
erythroid proliferation, adequate supplementation is manda-
tory for an optimal effect of ESA.104 Furthermore, FD
produces oxidative vascular injury by potentiating uremic
inhibition of homocysteine catabolism.105
Vitamin C deficiency
Unlike other animals, human subjects solely depend on
dietary source for ascorbic acid, as it lacks the capacity for its
endogenous synthesis. Vitamin C is a cofactor for several
enzymatic metabolism.106 Owing to its water solubility, there
is a greater loss of vitamin C in subjects undergoing hemo-
diafiltration compared with those on peritoneal dialysis.101,107,108
Furthermore, an increased risk for vitamin C deficiency occurs
in a sub-population (of Asian) with haptoglobin gene
polymorphism (hp 2-2).109
In addition, ascorbic acid promotes gastrointestinal
absorption of iron and enhances its mobilization from tissue
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stores. It increases Hb synthesis by facilitating incorporation
of Fe into protoporphyrins. Vitamin C, an anti-oxidative
free oxygen scavenger, downregulates hepatic synthesis of
cytokines.110–113 Its intravenous use in HD subjects reduces
serum level of ferritin, an inflammatory biomarker.110–113 As
symptoms of vitamin C deficiency (namely anemia, asthenia,
myalgia) are similar with the findings in CKD, early diagnosis
is often jeopardized.111,112 Therefore, its deficiency must be
considered in the event of persistent anemia that failed to
respond to EPO and Fe supplements.
Circulating EPO inhibitors
Resistance to biological effects of EPO may result from its
neutralization by a circulating antibody or by its inactivation
by binding the soluble plasma receptors (Figure 3).114 Pure
red cell aplasia is a rare cause of anemia that results from
antibody neutralization of EPO. It was seen with higher
frequency (191 events) in Europe between 1998 and 2002. It
could have resulted from a substitution of polysorbate-80
emulsifier for human albumin in the formulation of ESA. Its
immunogenicity was enhanced by subcutaneous administra-
tion and certain host biological factors. Incidence of pure red
cell aplasia decreased with the removal of offending EPO
(Eprex) from the European market.115
Pure red cell aplasia should be suspected in a patient who
had received ESA therapy for44 weeks and had experienced
a rapid decrease in Hb mass (40.5 g/dl per week), reduction
in absolute reticulocyte count o10, 000 per ml, and/or
41Unit per week of red cell transfusion.116–118 Non-
erythroid cell lines including leucocytes and platelets are
normal. The more common causes of EPO-resistant anemia
should be excluded. There is an absence of erythroid
precursors on bone marrow sampling and low EPO content
of the serum. The serum sample inhibits growth of erythroid
colonies in a bone marrow culture. Radioimmunoassay
identifies circulating neutralizing anti-EPO IgG.119 Disconti-
nuation of rhEPO will result in rapid fall of the neutralizing
antibody. Steroid and/or calcineurin inhibitor may be
successful.120 Poor response may warrant plasma exchange
and/or allograft transplantation. Routine blood transfusion
should be avoided except for life-threatening anemia.
Hematide, a pegylated synthetic peptide, which is immuno-
logically distinct from EPO, has been used to minimize cross-
reactivity.121
POTENTIAL PHARMACOLOGICAL INTERVENTION IN EPO
RESISTANCE
Although rarely used, certain aspects of EPO resistance may
be amenable to drug intervention. Thus, there are ongoing
clinical trials on anti-oxidative agents, nutritional supple-
ments, and stimulants of endogenous erythropoiesis.
Anti-inflammatory agents
Delivery of vitamin E, either by impregnation of HD filters or
by its oral therapy, reduces oxidative hemolysis that results
from chronic dialysis. Similarly, a-tocopherol protects
vitamin A, ascorbic acid, and polyunsaturated fatty acids
from inactivation by free radicals.122,123 Furthermore, there
is an ongoing European clinical trial on the efficacy of
Oxpentifylline (a xanthine derivative) as an inhibitor of
inflammatory cytokines (IL-1 and tumor necrosis factor-a)
among dialysis subjects.124,125 Similarly, by improving
cytokine profiles, anti-lipemic agents promote responses to
EPO, an effect that may occur even in the absence of
hyperlipidemia.126
Nutritional supplements
To maintain an efficient erythropoiesis, there must be
adequate supply of essential hemopoietic nutrients. These
include iron, folic acid, copper, vitamin C, vitamin B12,
a-lipoic acid, and levocarnitine. a-lipoic acid is a coenzyme
of mitochondrial dehydrogenase that is required for the
synthesis of ATP. It suppresses oxidative stress, in part by
depleting serum concentration of symmetric-dimethyl argi-
nine.127 Similarly, L-carnitine promotes efficient utilization of
cellular energy by enhancing mitochondrial transfer of fatty
acid. It stimulates heme oxygenase-1, an antioxidant that
shares metabolic pathway with EPO.128 Carnitine deficiency
may result from excess catabolism and losses from dialysis
procedures. Consequently, its intravenous replenishment is
associated with lower EPO requirement, lesser oxidative bio-
markers, and positive nitrogen balance.129–131
Long-acting EPO
Concern for the adverse effects of excessive EPO has led to
the synthesis of product with larger molecular weight and
longer elimination half-life. Thus, a more efficient erythro-
poiesis (and lower side effects) is promoted by prevention of
wide oscillation in biological activity that characterizes the
short-acting variant.
Darbepoietin-a. Using insertion mutagenesis to increase
the N-linked glycosylated (bonding) sites for sialic acid
residues, ESA with a larger molecular weight was synthesized.
Its elimination half-life was increased by more than threefold.
Thus, a weekly subcutaneous dose of darbepoietin effectively
corrects anemia in most CKD subjects.132,133 Unlike short-
acting EPO, its use in cancer patients did not result in disease
progression or lower survival rate.133
Continuous EPO receptor activator. Continuous EPO
receptor activator was synthesized by integration of EPO
protein with a polyethylene (glycol) polymer, thereby
increasing its half-life to 130 h. Anemia was successfully
controlled after a twice monthly regimen in a recent phase III
clinical trial.132
EPO fusion with human IgG. Additional strategy aimed at
increasing EPO potency is the genetic fusion of its N terminal
with the Fc region of human IgG. It allows binding of the
(aerosolized) EPO conjugate with Fc receptors on epithelial
lung surfaces and thereby facilitates its active transportation
into the systemic circulation.134 The feasibility of its clinical
application was recently shown by a successful conduct of a
phase I human trial.132
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EPO-mimetic peptide. Pegylated peptide (Hematide) dif-
fers from EPO in its homology sequence, but has greater
(1000-fold) affinity for its receptor and therefore has a longer
biological half-life. Owing to its low immunogenicity, it is
used as rescue therapy in EPO antibody-mediated red cell
aplasia.132
Endogenous induction of EPO
Furthermore, the potential for avoiding morbidities from
excessive EPO (and/or EPO resistance) is more likely with
strategies that exploit the capacity for endogenous EPO
production.
Prolyl hydroxylase inhibition (HIF stabilizers). HIF is a trans-
criptional complex that regulates EPO gene expression by
oxygen.132 In iron-replete cells, its a-subunits are degraded by
prolyl hydroxylase, a process that requires 2-oxoglutarate as a
cofactor. Therefore, analog substitution of the cofactor with
N-oxalylglycine (HIF stabilizers) activates transcription of
EPO synthesis. A unique advantage of this agent is its
capacity for an oral administration. In addition, HIF
stabilizers facilitate iron recycling by upregulating (hypox-
ia-sensitive) genes for EPO receptors, transferrin, and
ferroportin.135 However, there is a credible concern that
coactivation of gene for vascular endothelial growth factor
may promote an off-target development of oncogenesis.135
Erythroid survival mediators. The protein product of
growth arrest-specific gene 6 (Gas6) mediates the survival of
erythroid cell lines. ESA stimulates erythroblast for the
release of Gas6, which in turn induces serine-threonine
kinase (Akt) for signal activation of the EPO receptor.136
Therefore, adjunct therapy with Gas6 gene by-product may
allow lower therapeutic doses of ESA. Unlike rhEPO, Gas6
produces no adverse effect of erythrocytosis.136 Similarly,
IL-3 regulates gene transcription (Gata-2 and Scl) for survival
of immature erythroid cells, whereas EPO increases (Gata-1)
mRNA and protein stability.137
EPO gene therapy. A successful clinical application of
gene therapy lies in the ability to purify and deliver the genetic
material while maintaining safety, cost efficacy, and biological
potency. The recent use of human mesenchymal stem cells,
as a vector for the hEPO gene in a mouse model, results in
a life-long control of Hb deficit, holding promise for its use
in human population.138 Given that stem cells are immune
privileged, a convenient intramuscular delivery every 2–4
times per year is feasible. Similar to endogenous EPO,
coupling of the gene with a hypoxia-responsive DNA element
may allow oxygen-dependent regulatory feedback.139 A
potentially viable and cost-effective technique for gene therapy
is the molecular engineering of viral proteins with the hope of
circumventing the natural barriers to its (viral) survival.140
In summary, the tremendous success recorded with the
use of EPO for control of anemia of CKD in the last two
decades is recently tempered by the concern for its safety
when administered at higher doses. Surveillance program for
early detection EPO resistance and strategies to minimize
their biological impact must be built into all renal programs.
Owing to the challenges in establishing diagnosis, often
the best proof for hemopoietic nutrient deficiency is a
therapeutic trial. Consequently, empirical supplementations
with Fe and similar nutrients are imperative. Finally, there
are upcoming therapeutic agents that exploit the capacity for
endogenous EPO synthesis in CKD subjects; and may
hopefully minimize the off-target effects of excess dosages.
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